ChartMill assigns a Buy % Consensus number of 87% to AVTX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-03-25 | Jefferies | Initiate | Buy |
| 2025-03-20 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-28 | Piper Sandler | Initiate | Overweight |
| 2024-12-19 | BTIG | Initiate | Buy |
| 2024-12-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2024-10-24 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-04-16 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2023-06-27 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-06-27 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-02-08 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-03-03 | RBC Capital | Maintains | Outperform |
| 2022-03-03 | Jefferies | Downgrade | Buy -> Hold |
| 2021-09-24 | RBC Capital | Initiate | Outperform |
15 analysts have analysed AVTX and the average price target is 34.39 USD. This implies a price increase of 117.65% is expected in the next year compared to the current price of 15.8.
The consensus rating for AVALO THERAPEUTICS INC (AVTX) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.